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type 2 diabetes by individual socio-economic
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Olga Grintsova, Werner Maier and Andreas Mielck*Abstract
Introduction: Quality of care could be influenced by individual socio-economic status (SES) and by residential area
deprivation. The objective is to synthesize the current evidence regarding inequalities in health care for patients
with Type 2 diabetes mellitus (Type 2 DM).
Methods: The systematic review focuses on inequalities concerning process (e.g. measurement of HbA1c, i.e.
glycolised haemoglobin) and intermediate outcome indicators (e.g. HbA1c level) of Type 2 diabetes care. In total, of
n = 886 publications screened, n = 21 met the inclusion criteria.
Results: A wide variety of definitions for ‘good quality diabetes care’, regional deprivation and individual SES was
observed. Despite differences in research approaches, there is a trend towards worse health care for patients with
low SES, concerning both process of care and intermediate outcome indicators. Patients living in deprived areas less
often achieve glycaemic control targets, tend to have higher blood pressure (BP) and worse lipid profile control.
Conclusion: The available evidence clearly points to the fact that socio-economic inequalities in diabetes care do
exist. Low individual SES and residential area deprivation are often associated with worse process indicators and
worse intermediate outcomes, resulting in higher risks of microvascular and macrovascular complications. These
inequalities exist across different health care systems. Recommendations for further research are provided.
Keywords: Type 2 diabetes mellitus, Health care, Socio-economic status, Regional deprivation, ReviewIntroduction
Type 2 diabetes mellitus (Type 2 DM) is one of the lead-
ing causes of death in the world with constantly increas-
ing prevalence: in 2008, the prevalence was estimated to
be 10% among adults aged 25+ years [1]. The rising bur-
den of diabetes is associated with a constant increase in
its complications, causing rising disability and booming
health care costs ranging from 2.5% to 15% of annual
health care budgets [2]. Good diabetes care is crucial to
delay these complications. Good glycaemic control results
in a reduction of complications and better patient out-
comes. The data from the United Kingdom Prospective
Diabetes Study (UKPDS) concerning patients with Type 2* Correspondence: mielck@helmholtz-muenchen.de
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unless otherwise stated.DM suggested, for example, a decreased risk of 25% in
retinopathy and nephropathy for every reduction of 1%
in HbA1c [3].
Different patient groups are affected unequally by
Type 2 DM. There are large differences, for example,
concerning gender, age and race. Socio-economic status
(SES) may influence access to and quality of care, social
support and availability of community resources. It may
also influence diabetes-related knowledge, communica-
tion with providers, treatment choices and the ability to
adhere to recommended medication, exercise and diet-
ary regimens [4,5]. Thus, low SES could be associated
with multiple risks. First, epidemiological studies have
repeatedly confirmed the inverse association between
Type 2 DM and SES [6-9]. Also, regional deprivation
(often used as a proxy for individual SES) was shown toral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lence of diabetes mellitus [10]. Second, some analyses fo-
cusing on patients with Type 2 DM indicate that health
care could be worse for low SES groups, but this has rarely
been studied in a systematic way.
To date, there is just one systematic review regarding
inequalities in health care among patients with Type 2
diabetes by individual socio-economic status (SES) and
regional deprivation. Ricci-Cabello et al. (2010) [11] focused
on countries from the Organisation for Economic Cooper-
ation and Development (OECD). They looked at differences
by gender, ethnic group and SES, and for SES they reported
results concerning diagnosis, control of diabetes and access
to health services (four, seven and five studies respectively).
They conclude that the results point towards health in-
equalities favouring higher SES groups, and that there is
a great need for more empirical research. Their review
covers publications up to 2007, and a number of papers
have been published since. Thus, it was our objective to
synthesize the current evidence, focusing on process and
intermediate outcome indicators of health care for patients
with Type 2 DM and on differences by individual SES and
residential area deprivation.
Methods
In November and December 2012, we conducted a sys-
tematic literature search in PubMed for original studies
published in English, German, French or Spanish. A com-
bination of the following key words was used: diabetes,
diabetes Type 2, quality of care, management, care, con-
trol, soci*, socio*, inequ*, differ*, dispar*, regio*, depriv*
(and their translations) in title and abstract. The American
Diabetes Association (ADA) guidelines for good dia-
betes control and quality of care were changed in 2002
(with subsequent improvements in 2005 and 2011) [12,13]
and, in 2005, the first Global Guideline for Type 2 Diabetes
was published by the International Diabetes Federation
(IDF) [14], complicating the comparison between previous
and later studies. In order to improve the compatibility
between studies, the time frame for the search was re-
stricted to papers published between 1 January 2002
and 13 December 2012.
Altogether, 886 publications were eligible for further
screening (see Figure 1). Titles and abstracts were screened,
using the inclusion criteria outlined below and the PRISMA
statement for reporting the results [15]. The references
from selected articles were screened for further poten-
tially relevant studies.
An article was included in the review: (a) if the study
population comprises Type 2 DM patients or a mixed
group of Type 1 and Type 2 DM patients; (b) if quanti-
tative analyses are presented concerning process and
intermediate outcome indicators of health care; (c) if indi-
vidual SES and/or residential area deprivation is includedas an independent variable. We focused the review on
process indicators such as assessment of HbA1c (glycolised
haemoglobin), BP (blood pressure), BMI (body mass index),
and on intermediate outcome indicators such as quantita-
tive measurement of HbA1c, BP and/or lipids in the blood.
All these indicators relate directly to health care provision,
they are usually well documented and show relatively
short-term results. They are influenced by other factors as
well, of course, including individual health behavior and so-
cial support. Health care plays an important role, though,
and most guidelines for good diabetes control include
targets such as reduction of high BP, smoking cessation
and reduction of high body weight.
Quality of care could also be assessed by outcome
indicators less closely associated with health care, such
as complications, hospital admissions or cardiovascular
disease (CVD) mortality [16]. Results concerning these
‘other outcome indicators’ are mentioned below just briefly.
The exclusion criteria are: studies restricted to Type 1
DM and studies just focusing on social disparities by
race, ethnicity and nationality or migration status. These
social disparities could be closely linked to individual SES
and residential area deprivation, of course, but we still be-
lieve that they touch on a different topic.
Different information was extracted from the studies
finally selected, based on the data extraction sheet proposed
by Aveyard [17]; the results are presented in Tables 1 and 2.
We also tried to assess and compare the methodological
quality of the studies; this task proved to be quite challen-
ging. The studies included in the review were conducted in
very different settings (e.g. hospital, primary care), using a
wide variety of methodological approaches (e.g. national or
local registry data, practice-level data, patient survey). It is
hardly possible to compare them in a common scheme that
would account for all these differences. Finally, we used an
adopted version of the EPHPP (Effective Public Health
Practice Project) quality assessment tool [18]. It includes
different components (evaluation of selection bias, study
design, confounders, blinding, withdrawals and drop-outs,
intervention integrity). Each component must be rated as
providing ‘strong’, ‘moderate’ or ‘weak’ evidence; the final
scale summarizes these ratings. We applied relatively strict
criteria: to be rated as ‘strong’ evidence, a study must have
no weak component and at least three out of six strong
ones. The criteria for ‘moderate’ evidence are: one ‘weak’
component, or no ‘weak’ and less than three ‘strong’ ratings.
All other studies were rated as ‘weak’. Screening, informa-
tion extraction and assessment was first performed by OG
and WM, in case of disagreement a joint decision was
reached together with AM.
Results
Based on the inclusion and exclusion criteria listed above,
32 articles were identified for full-text review (see Figure 1).
Table 1 Quality of health care for people with type 2 diabetes: process and intermediate outcome indicatorsa
Process indicators: delivery of assessment Intermediate outcome indicators: quantitative measurementb
Ref. HbA1c Lipids Retino- pathy BP BMI Smoking Micro-albuminuria HbA1c Lipids BP (mmHg)
[19] X X X ─ ─ ─ ─ ─ ─ ─
[20] X ─ ─ X X ─ ─ Mean Mean1 Mean
[21] ─ ─ ─ ─ ─ ─ ─ Mean ─ Mean
[22] ─ ─ ─ ─ ─ ─ ─ Mean ─ ─
[23] ─ ─ ─ ─ ─ ─ ─ Mean > 2 g/L3 ─
[24] ─ ─ ─ ─ ─ ─ ─ ≤ 7.4% ≤ 5 mmol/L1 ≤ 145/85
[25] X X X ─ ─ ─ ─ Mean Mean2 > 140/90
[26] ─ ─ ─ ─ ─ ─ ─ Mean < 100 mg%2 ─
[27] X X X ─ ─ ─ X ─ ─ ─
[28] X X X X X X X ≤ 7.4%; ≤ 10% ≤ 5 mmol/L1 ≤ 145/85
[29] X X ─ X ─ X ─ ≤ 7.4% ≤ 5 mmol/L1 ≤ 140/80
[30] ─ ─ X ─ X X X < 7.5%; < 10% ≤ 5 mmol/L1 < 145/85
[31] X X ─ ─ ─ ─ ─ ─ ─ ─
[32] ─ ─ X ─ ─ ─ ─ Mean ≥ 54 ≥ 140/90
[33] X X ─ ─ X X ─ Mean; ≤ 7.5% ─ ─
[34] ─ ─ ─ ─ ─ X ─ ≥ 6.5% ≥ 2.58 mmol/L2 ─
[35] X X X X X X X ≤ 7.4%; ≤ 10% ≤ 5 mmol/L1 ≤ 145/85
[36] ─ ─ ─ ─ ─ ─ ─ ≤ 6.5% ≤ 5.2 mmol/L1 ≤ 140/90
> 1.1–1.4 mmol/L2
[37] X ─ X X ─ ─ X < 7.0% < 100 mg/dL2 < 130/80
[38] X X ─ X X ─ ─ ≥ 9% < 100 mg/dL2 ─
[39] X X X X X X ─ ≤ 7.0% ≤ 2.6 mmol/L2 ≤ 130/80
1Total cholesterol; 2LDL; 3TG; 4Total cholesterol/HDL-coefficient.
aother process and outcome indicators are just mentioned in the text (see ‘Results’).
bmean values or cut-off values for ‘good quality health care’.
HbA1c, glycolised haemoglobin; BP, blood pressure; BMI, body mass index.






Assessment of full-text 
articles (n = 32)
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(n = 86)
Studies included in the 
review (n = 21)
Full-text articles excluded
(n = 11) 
Figure 1 Selection of articles.
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Table 2 Characteristics of the studies




Main results Main conclusion
- n
-% women
- type of diabetes
- age (years)
1 2 3 4 5
Arday D.R. et al. [19] - USA – ZQ score (household
income; education;
occupation; home value)
- HbA1c tests (sign.), eye examinations
(sign.) and lipid profile measurements
(sign.) less likely for patients living in
the most deprived regions
- Worse diabetes care in the most
deprived states
- n = 1,941,517
- 54.4%
- T1D + T2D - Substantial reduction in variation
between states concerning diabetes




Bachmann M.O. et al.
[20]
- UK Educational level, individual
income
– - Higher HbA1c values (sign.), more
non-compliance (sign.), retinopathy
(trend) and less hospital attendance
(sign.) among patients with low
education
- Larger burden of morbidity for
patients with low SES, but less
hospital care- n = 555
- 47%
- T1D + T2D
- 65 (mean) - More complications among patients
with low education and low income
(sign.)
- More negative effects on social life
(sign.) and personal life (sign.) among
patients with low education and low
income
Bäz L. et al. [21] - Germany Index based on educational level,
occupational status and income
– - Increasing HbA1c (sign.) and BMI
(sign.) with decreasing SES
- Worse diabetes control for
patients with low SES
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Bebb C. et al. [22] - UK – Townsend score - Higher HbA1c values for patients
living in the most deprived regions
(sign.) and for practices with many
patients living in the most deprived
regions (sign.)
- Worse glycaemic control in the
most deprived regions
- n = 1,534
- 41%
- T2D - Effect of regional deprivation most
important for extreme deprivation
- 18–80
66.2 (median) - Variation between practices
concerning HbA1c values largely
explained by percentage of patients
living in the most deprived regions
1 2 3 4 5
Bihan H. et al. [23] - France EPICES score – - Higher HbA1c values (sign.), more
complications such as retinopathy
(sign.) and neuropathy (sign.) and
fewer 1-day hospitalizations (sign.) in
patients with low SES
- Worse glycaemic control and more
microvascular complications in
patients with low SES- n = 135
- 48.8%
- T1D + T2D
- 59 (mean)
Bottle A. et al. [24] - UK – IMD - Age group 25–59 years: higher total
hospital (sign.) and ketoacidosis
admission rates (sign.) for patients
living in the most deprived regions
- Worse diabetes control, more
hospital admissions and lower quality
of health care in the most deprived
regions
- n = 1,760,898
- (unknown)
- T1D + T2D;
- 25–59 - Age group ≥60 years: higher total
hospital admission rates (sign.), lower
total quality score (not sign.) and
lower HbA1c control score (not sign.)
for patients living in the most
deprived regions
25–59 (main group, 47.9%)
Brown A.F. et al. [25] - USA Educational level, income – - Small SES differences concerning six
out of seven process indicators, i.e.
lipid profile measurement, foot
examination, aspirin advice or use,
influenza vaccination (all not sign.)
and in two out of three intermediate
outcomes, i.e. HbA1c control (not sign.)
and LDL control (sign.)
- Worse diabetes control for patients
with low SES concerning glycaemic
control and dilated eye examinations- n = 7,456
- 53%
- T1D + T2D
- 60.4 (mean)
- Higher HbA1c values (sign.) and
fewer dilated eye examinations
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- Higher HbA1c values for patients
living in more deprived regions
(not sign.)
- Tendency for worse glycaemic
control in most deprived regions
- n = 7.288
- 47.4%
- T1D + T2D - No association between regional
deprivation and LDL control
- 62 (mean)
Gnavi R. et al. [27] - Italy Educational level, income – - Fewer measurements of HbA1c
(not sign.) and eye examinations
(not sign.) among patients with
low education
- Most SES differences not
statistically significant
- n = 33,453 - SES differences in health care
processes favouring the
disadvantaged group- 49.4% - Fewer ECG measurements (not sign.)
and visits to diabetologists (not sign.)
among patients with low education
or low income
- T1D + T2D
- 65–74
65–75 (main group 34.3%)
1 2 3 4 5
Gray J. et al. [28] - UK – IMD - Small difference concerning
health care process between most
and least deprived regions
- Tendency for worse health care
in the most deprived regions
- n = 6,035
- Higher values of HbA1c (not sign.)
and BP (not sign.) for patients living
in the most deprived regions
- 48.3%
- T1D + T2D
- 65–74 (main group,
26.6%)
Guthrie B. et al. [29] - UK – Carstairs deprivation
score
- Less complete process indicators
of good quality health care for
patients living in the most deprived
regions (sign.)
- No consistent association
between quality of care and
regional deprivation- n = 10,191
- 47.1%
- T2D
- 67.8 (median) - Higher percentage of smokers for
patients living in the most deprived
regions (sign.)
Hippsley-Cox J. et al. [30] - UK – Townsend score - Higher BMI (sign.), more smokers
(sign.), less neuropathy (sign.),
microalbuminuria (sign.) and eye
examinations (sign.), fewer flu
vaccinations for patients living in
the most deprived regions
- Worse process of care and
worse outcomes in the most
deprived regions- n = 53,678
- (unknown)
- T1D + T2D
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Hsu C.C. et al. [31] - Taiwan Income – - More severe diabetes symptoms
(sign.), fewer visits to diabetes clinic
(sign.) and to ambulatory diabetes
clinic (sign.) in low SES group
- Higher probability of
hospital-diagnosed diabetes
following severe symptoms and
smaller likelihood of receiving
recommended diabetes check-ups
for patients with low SES
- n = 1,462
- 39.3–50.4%
- T2D
- > 20 - Fewer tests for HbA1c (sign.), LDL
(sign.), triglycerides (sign.) and fewer
examinations for retinopathy (sign.)
in low SES group
Icks A. et al. [32] - Germany Helmert index (based on
educational level, occupational
status, income)
– - Unfavourable process (retinopathy
screening, foot examination, diabetes
education, lipid and BP control, all
not sign.) and outcome (HbA1c,
not sign.) indicators in low SES group
- Preliminary indications of less
than good health care especially
for patients with low SES- n = 149
- 46% - Less knowledge about the term
‘HbA1c’ in low SES group (sign.)
- T2D
- 62 (mean)
1 2 3 4 5
James G.D. et al. [33] - UK – Townsend score - Higher values of HbA1c in most
deprived regions (sign.)
- Worse glycaemic control in
deprived regions, independent of




Larranaga et al. [34] - Spain – Index from Basque
Institute of Statistics
- Higher values of LDL (sign.) and
HbA1c (sign.) in most deprived
regions
- Worse health care and higher
prevalence of clinical complications
in most deprived regions- n = 2,985
- 52%
- T2D - Higher risk of macroangiopathy
complications (sign.) and higher
risk of retino-, neuro- and
nephropathy (not sign.) in most
deprived regions
-≥ 24
- More consultations per year in
most deprived regions (sign.)
Millet C. et al. [35] - UK – IMD - Lower rates of reaching health
care targets concerning HbA1c,
BP and cholesterol in most
deprived regions
- Worse intermediate outcomes in
most deprived regions
- n = 1,852,762
- unknown
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Reisig V. et al. [36] - Germany Helmert index (based on
educational level, occupational
status, income)
– - Among patients with T2DM and
myocardial infarction: lower
probability of reaching HbA1c
target (sign.) and higher prevalence
of retinopathy (sign.) in low SES
group
- Worse glycaemic control and
more complications for patients




Shani M. et al. [37] - Israel Income – - Lower probability of reaching
HbA1c target (sign.) and LDL target
(sign.) in low SES group
- Worse glycaemic control for
patients with low SES
- n = 18,316
- 50.3%
- T1D + T2D
- 65.5 (median)
1 2 3 4 5




- ‘Optimal follow-up’ (sign.) is more
likely in most deprived regions
- Process indicators: better health
care quality in the most deprived
regions- n = 74,953
- 46.1%
- T1D + T2D - Appropriate LDL control (not sign.)
and achieving HbA1c target (sign.)
less likely in most deprived regions
- Intermediate outcome indicators:
worse health care quality in the
most deprived regions- 59 (mean)
Wong K.W. et al. [39] - China Fee for service waiver (yes/no) – - Recording of cholesterol (sign.)
and of BMI (sign.), screening for
nephropathy (sign.) and retinopathy
(sign.) less likely in low SES group
- Process indicators: worse health
care for patients with low SES
- n = 1,970 - Achievement of BP target (sign.)
and HbA1c target (not sign.) less
likely in low SES group
- Intermediate outcome indicators:
worse health care for patients




T1D, Type 1 diabetes.
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(no data on individual SES or regional deprivation, no data
on quality of health care, or no analysis of the association
between these two topics).Most of the remaining 21 papers
are from Western European countries, i.e. from the UK
(n = 8), Germany (n = 3) and one each from France, Italy
and Spain. There are also three papers from the USA,
two from Israel and one each from Taiwan and China.
They comprise cross-sectional (n = 12) and cohort studies
(n = 9), and most used the retrospective data (n = 17). Some
(n = 8) are limited to Type 2 DM patients; the others use a
mixed sample of both Type 1 and Type 2 DM patients.
Sample size varies between 135 and 1,941,517 patients;
mean (or median) age varies between 52.6 and 68.1 years.
The process and intermediate outcome indicators (including
cut-off points of good control) are presented in Table 1.
The main characteristics and results of the studies are
summarized in Table 2.
Individual SES and regional deprivation
Individual SES was assessed in 10 studies, mostly by
income [31,37,39] and educational level. These two indi-
cators were used side by side [20,25,27] or combined with
the indicator ‘occupational status’ in order to build an
index of SES [21,23,32,36]. The association between re-
gional deprivation and quality of health care was evaluated
in 11 studies. In five of them (all from the UK), this was
the primary objective of the study, using different tools
to assess regional deprivation, i.e. the Townsend score
[22,30,33], the Carstairs deprivation score [29] and the
Index of Multiple Deprivation (IMD) [24,28,35]. In the
other three studies, regional deprivation was used as a
proxy for individual SES. In one study from the USA, the
ZQ score (zip quality ranking of participant’s residence,
based on economic indicators for the state) was used as a
very broad measure for individual SES [19]. In the other
three studies from the USA, Spain and Israel, individual
SES was assessed by neighbourhood SES using census
data combined with GIS (geographic information system)
[26] or local standard of living data [34], or by using the
economic ranking of the geographical sub-district where
the patients lived [38].
Quality of care indicators
Three groups of process indicators can be distinguished: (a)
delivery of clinical parameter assessments (e.g. concerning
HbA1c, lipid profile, BP, BMI, retinopathy examinations
by the physician); (b) smoking, as it is well established
that Type 2 DM patients should not smoke; (c) visits
to a GP (General practitioner) or a diabetologist. The
intermediate outcome indicators are: numerical value
of clinical parameters (e.g. concerning HbA1c, lipid
profile, BP, BMI) as compared with established cut-off
points for good control.The process indicators used most often are presented in
Table 1. Further process indicators included, for example,
complications [20,25,30-32,35], creatinine [23,28-31,35],
flu vaccination [25,28,30,35], microalbuminuria test
[27,28,30,34,36], pulses [28,30,35], attendance at general
practices [20], angiotensin converting enzyme inhibitors
received in the presence of proteinuria or microalbuminuria
[30,35], adherence [20], use of or advice to use aspirin [25],
ECG [27], proportion of diabetic patients who were diag-
nosed through hospitalization [31], diabetes education and
knowledge of ‘HbA1c’ definition [32], sedentary lifestyle
[34]. Several composite process indicators have been
used as well: based on a patient questionnaire [20], on
an assessment of HbA1c and at least two assessments out
of three (eye, total serum cholesterol, microalbuminuria)
per annum [27], on the performance of all tests out of
seven (HbA1c, LDL [low-density lipoprotein]), nephropathy
monitoring, eye and foot examinations, BP, BMI recorded
during the past 12 months) [39].
Concerning the intermediate outcome indicators, the
cut-off points for good control vary greatly. For HbA1c,
for example, they vary from ≥ 6.5% [34] or ≤ 6.5% [36]
to ≥ 9% [38] or ≤ 10% [28]. Based on international guide-
lines [40], the cut-off points for lipids used most often
are LDL ≤ 100 mg% or ≤ 2.6 mmol/L [25,26,34,37-39].
For total cholesterol, many studies use ≤ 5 mmol/L as
the cut-off point for good control [24,28-30,35]. Other
measures are used as well, e.g. concerning hypertrigly-
ceridaemia [23], coefficient ‘total cholesterol/HDL’ [32]
and HDL [36]. BP level was used in 11 studies: the cut-
off points vary from < 130/80 [37] to ≤ 145/85 [24].
Looking also at other outcome indicators, some studies
assessed health care quality by the presence of complica-
tions [23,32,36], high creatinine level [23,36], presence of
anaemia [23], total and ketoacidosis hospital admissions
[24,27], absence of obesity (BMI ≥ 30 kg/m2) [36], propor-
tion of non-smokers [29,36] and proportion of patients with
high physical activity (more than 1 hour per week) [36]. In
all but two studies [21,35], the results were adjusted for age
and sex. Also, many results were adjusted for diabetes dur-
ation [20-23,25,29,31,32,34,36,39] and BMI [21,23,33,37,39].
Associations with individual SES
Most studies show that lower individual SES is associated
with worse diabetes care. These disparities are reported for
both process and outcomes of diabetes care. Concerning
process indicators, most of these differences are statistically
significant [31,39] or show a similar trend [20,25,32].
Low SES patients visit diabetes clinics and ambulatory
care facilities less often [31], but they are also more
likely to visit a diabetologist [27], probably reflecting a
greater need for better diabetes control. Two studies
show no major difference by individual SES [37] or only
slight differences in dilated eye examination rates [25].
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health care processes [27].
Turning to the intermediate outcome indicators, the
results differ substantially by the indicator used. In all
studies looking at individual SES and glycaemic control,
lower SES patients have higher HbA1c values than other
patients, either significantly [20,21,23,25,36,37] or as a
similar trend [32,39]. Socio-economic position is im-
portant even at the practice level: a higher proportion
of patients with low SES registered at a practice is sig-
nificantly associated with a lower percentage achieving
good control (HbA1c < 7 mg%) [37]. The association
between individual SES and BP is investigated in seven
studies, and no significant association is found in six of
them [20,21,25,32,36,37]. In the other study, the chance of
low SES patients achieving the BP target is reduced by
about 30% (p <0.05) [39]. The achievement of clinical
targets for lipid control is assessed in seven studies, and
no significant association with individual SES is found
in five of them [20,23,32,36,39]. In the other two stud-
ies, low SES is significantly associated with worse lipid
control [25,37]. Concerning the other outcome indica-
tors, it has also been shown that low SES patients are
more likely to have complications such as retinopathy
[20,23,36] and nephropathy [20].
Associations with regional deprivation
In most of the studies reviewed here, high regional
deprivation is associated with worse diabetes care.
Concerning process indicators, the results are somewhat
contradictory. The most deprived group is likely to have
the clinical parameters measured least often; these differ-
ences are significant [19,29,30] or point into the same direc-
tion [28,35]. There are exceptions though. One study shows
that optimal follow-up (i.e. all process indicators recorded)
is significantly associated with low regional deprivation
[38]. In another study, GP consultations are significantly
higher in the most deprived region [34]. It can be hypoth-
esized that ‘consultation efficiency’ is especially low for
low SES patients, that they need more visits than high SES
patients for achieving the same target.
Concerning intermediate outcome indicators, the asso-
ciation with HbA1c is investigated in 10 studies. In nine
of them, higher regional deprivation is associated with
higher HbA1c values, and patients living there achieve
the glycaemic control targets less often; these differences
are statistically significant [22,30,33,34,38] or show a simi-
lar trend [24,26,28,35]. No difference between deprivation
groups was found in just one study [29]. The achievement
of BP targets is investigated in five studies, and in three of
them the high deprivation group shows more unfavour-
able results, either significantly [30] or as a trend [28,35].
No association is found in two studies [24,29]. Lipid con-
trol is investigated in eight studies, and in four of them nosignificant association is found [24,28-30]. In the other
studies, there was a clear trend indicating that patients
living in deprived areas [26,34,38] or visiting practices
in deprived areas [35] are less likely to achieve the lipid
profile control targets. Concerning the other outcome
indicators, patients from the most deprived regions often
experience a greater burden of disease and show signifi-
cantly higher risks of complications [34] and diabetes-
related hospital admissions [24]. Also, the proportion of
smokers is higher [29,30] and so is the mean BMI [30].
Following our quality assessment criteria (see ‘Methods’),
‘strong’ evidence is provided by just three studies, they have
been conducted in the USA [19], the UK [35] and Israel
[38]. The data were taken from registries with high data
quality, making problems of selection and reporting bias
highly unlikely. The results were adjusted for age, sex,
duration of diabetes and other variables, and the process
and outcome indicators of health care quality were
chosen according to international guidelines [13,14].
The studies show that the values for process indicators are
worse in more deprived regions [19], and that intermedi-
ate outcome targets (e.g. concerning level of HbA1c) are
reached less often in more deprived regions, in the UK
[35] as well as in Israel [38].
Discussion
Studies included here come from a variety of countries,
and they vary widely in study design and sample size.
About one third use data from registries at the national
[19], regional [24,26,27,29-31,35,37,38] or practice level
[20,28,33,34]. These registries usually provide high quality
data with few missing values, but they mostly lack infor-
mation on individual SES. Other studies were conducted
in a hospital setting [21,23,39], and again data quality
should be high. Owing to potential selection bias, it could
be difficult, though, to apply the results to the general
population. A third group of studies is based on surveys
[22,23,32,36]. They might be more representative of the
whole population, but they often lack information regard-
ing process indicators. Each study design has its specific
advantages and drawbacks, and this also applies to the
studies included in this review.
About half of the studies include information on indi-
vidual level SES, for example by educational level or per
capita household income (see Table 2). The other studies
include information on regional deprivation, probably
often because data on individual SES were not available
and regional deprivation was taken as a proxy. Regional
deprivation is assessed in different ways, e.g. by the Town-
send score [22], the IMD [24] or by a deprivation score
developed in Spain [28]. Individual level SES and regional
deprivation could both reveal important information, as it
could be important to improve health care for specific
social groups and/or for specific regions.
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is no unified, internationally accepted definition concern-
ing the quality of health care for people with Type 2 DM.
Different approaches to defining and measuring health
care quality are used, and it is hardly possible to combine
the results in a quantitative meta-analysis. Also, different
studies use different sets of indicators. Microalbuminaemia
is assessed in just five of these 21 studies, for example, and
six studies do not include any process indicator. All but
three studies include an intermediate outcome indicator
(e.g. comparing HbA1c values with a cut-off value for
good glycaemic control), but different cut-off values are
used in different studies, making it even more difficult
to directly compare the empirical results.
Despite these multifaceted differences between the 21
studies reviewed here, it is still possible to identify some
main results: (a) Process indicators of health care quality
are often significantly associated with individual SES, i.e.
patients with low SES often receive these measurements
and assessments less frequently than patients with high
SES (e.g. concerning HbA1c, lipids, retinopathy, BP, BMI,
smoking status, microalbuminaemia). (b) Individual SES is
often significantly associated with poor glycaemic control,
i.e. HbA1c values above the recommended clinical target.
(c) Concerning BP and lipids above the proposed level,
there seems to be no clear association with individual SES.
(d) Diabetes-specific complications such as retinopathy
and nephropathy seem to be more common among
patients with low (as compared with high) individual
SES, but these associations have rarely been assessed.
(e) The associations with health care quality are mostly
less pronounced and consistent if social differences are
assessed by regional deprivation instead of individual level
SES. (f) Concerning process indicators, some studies indi-
cate that health care quality is worse in more deprived re-
gions, but these associations are statistically significant
only in some of them. (g) A similar, but more consistent
picture is seen for glycaemic control. HbA1c values indi-
cating poor glycaemic control are found more often in
more deprived regions, and in most studies this difference
is statistically significant. (h) Some studies indicate that
the targets concerning BP and lipids are achieved less
often in more deprived regions, but the level of statistical
significance is reached only in some of them. (i) Few studies
assess the association between regional deprivation and
diabetes-specific complications such as retinopathy and ne-
phropathy; they indicate that it is positive and significant.
Some limitations of the review need to be considered.
First, we tried to find all relevant studies published up to
December 2012, by following a well established, stan-
dardized scheme [15], by including all papers irrespect-
ive of the statistical significance of their empirical
results, by including papers written in different lan-
guages (i.e. English, German, French and Spanish) andby performing a counter-checked evaluation of the papers.
Our search was confined to publications that could be
found in the PubMed database. Following the recommen-
dation from a reviewer we later repeated the search in the
EMBASE database (using the identical strategy as outlined
above; see ‘Methods’), and we found that all publications
identified in EMBASE had also been included in the
first group of papers (n = 886) identified in PUBMED
(see Figure 1). But of course we cannot rule out the
possibility that we have missed relevant publications.
Second, just one third of these studies are clearly re-
stricted to Type 2 DM patients [22,29,31-34,36,39], i.e. the
others also include Type 1 DM patients. This should not
be a major problem, though, as Type 2 DM accounts for
about 90% of all diabetes patients [1]. Of course, there
could also be important inequalities concerning health
care for type 1 DM [10], but this review focuses as
much as possible on type 2 DM. Third, social inequalities
can be assessed by a number of indicators besides SES and
regional deprivation (e.g. migrant status and ethnicity).
These other indicators are not included here, although they
might well interact with SES and regional deprivation [5].
The review could be an important contribution to the
discussion on health care inequalities among patients
with Type 2 DM. Most would agree that these inequal-
ities should be reduced, but to date there seems to be
just one review that summarizes the results and stresses
the need for further research. The previous review from
Ricci-Cabello et al. [11] covered publications up to 2007
and included 25 papers for final assessment; just two of
these are included in our review as well [34,36]. This little
overlap is also due to the fact that the two reviews differ
in a number of ways: The review from Ricci-Cabello et al.
[11] also includes studies that define social inequalities by
gender and ethnic group, that study inequalities in diagno-
sis of DM, and it includes four studies that are restricted
to type 1 DM.
Adding some recommendations for further research,
we would like to highlight eight topics: First, despite the
great variety of proposals regarding appropriate assess-
ment methods [16,41,42], quality of diabetes care should
be measured in a way that enables benchmarking and
comparison. A standard set of indicators for assessing
good quality health care should be provided. Process indi-
cators may not be a good predictor of patient outcome;
thus, it would be better to assess patient outcomes directly
[43]. For example, concerning intermediate outcome indi-
cators, the same cut-off value should be used in all studies,
preferably based on current international guidelines. This
is easier said than done, of course; there are still different
guidelines. Concerning cut-off points for ‘poor glycaemic
control’, for example, it has been proposed to use HbA1c
values above 6.5% [14] or 7% [13]. The National Diabetes
Quality Improvement Alliance [44] suggests HbA1c levels
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cut-off points, especially for the elderly [12]. The standard
set should also include outcome indicators.
Second, it is important to distinguish clearly between
the individual and the regional level. Assessing SES at
the individual level highlights the following problem:
health care for people with Type 2 DM could be influenced
by a number of individual risks and resources such as poor
health behaviour or good social support. It would be im-
portant to know which of these risks (or resources) are es-
pecially strong (or weak) among patients with low SES and
how their risks could be reduced and their resources im-
proved. Assessing SES by regional deprivation points to an-
other problem: resources for people with Type 2 DM could
differ between regions. There could be differences concern-
ing health care (e.g. availability of specialized physicians)
and other factors such as facilities for physical activities.
Important questions would be, for example: What kind of
resources are especially weak in more deprived regions,
and how could they be improved? What role could be
played by improving health care? Also, it is possible that
the proportion of patients with low individual SES is espe-
cially high in the most deprived regions, that the differ-
ences between regions could largely be explained by these
individual level differences. Therefore it is necessary to
differentiate clearly between effects at the individual and
at the regional level, i.e. to conduct multilevel analyses.
These analyses are well known in public health research
[45], but we are not aware of a study on social and regional
inequalities in health care for patients with Type 2 DM that
is based on this kind of analysis.
Third, some associations with low individual SES seem
to be fairly well established, concerning process indicators
(e.g. less frequent measurement of HbA1c and lipids),
intermediate outcome indicators (e.g. higher prevalence
of HbA1c values above the proposed level) and diabetes-
specific complications (e.g. higher prevalence of retinopathy).
Some associations with regional deprivation seem to
be fairly well established as well, concerning intermedi-
ate outcome indicators (e.g. HbA1c values) and diabetes-
specific complications (e.g. retinopathy). The potential
reasons behind these associations are poorly under-
stood however. They may relate to social differences in
training, awareness of early symptoms and compliance
[40,46,47], for example, but the ‘web of causation’ has
not yet been described in any detail. Health outcomes
are influenced by many factors, and health behaviour
plays an important role in explaining social differences
[48]. The influence of health services may be limited
[41], but it would be important to study the interplay
between health care, on the one hand, and health be-
haviour, diabetes self-management and the achieve-
ment of clinical targets, on the other, especially among
low SES patients.Fourth, meta-analyses could be important especially
for assessing effects that are relatively small. It is rather
difficult to merge the empirical information from different
studies (as mentioned above), but the chances to conduct
meta-analyses should be explored in more detail. Fifth,
registries provide an excellent database for these studies,
but they often lack information on individual SES such as
educational level or income. It is recommended that this
information is added wherever possible. Sixth, different
countries have different systems of health promotion and
health care (e.g. concerning co-payments), and the prob-
lems and causes of social inequalities in health care may
differ as well. One implication is that policy recommen-
dations for a specific country will have to be based on
empirical studies conducted in this country. Another
implication is that cross-country comparisons are diffi-
cult to conduct, as all these differences will have to be
taken into account, but these comparisons offer an im-
portant chance for studying the associations between
system characteristics and health care inequalities. Sev-
enth, health care for patients with type 2 DM is similar
to health care for patients with type 1 DM, but the two
groups of DM patients are quite different. It would be
important to add a review focused on patients with type
1 DM. Last but not least, there is a great need for inter-
vention studies, i.e. studies that compare different inter-
ventions aimed at reducing social differences in health
care for people with Type 2 DM.
Conclusion
The available evidence clearly points to the fact that
socio-economic inequalities in diabetes care do exist. Low
individual SES and regional deprivation are often associated
with worse process indicators of care and worse intermedi-
ate outcomes (e.g. poor glycaemic, lipid and BP control),
resulting in higher risks of microvascular (e.g. retinopathy)
and macrovascular complications (e.g. myocardial infarction,
stroke). These differences exist even in countries with
a health care system that is clearly based on solidarity
between all socio-economic groups (e.g. Germany).
Much is known about good quality diabetes care; it is
important to study in more detail why patients with
low SES profit less from this knowledge.
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